PF-Atlas › Clinical Trials › NCT01608555
Tobramycin 300 mg Once-a-day Aerosol in Adults With Cystic Fibrosis
tobramycin · Phase 4
Registry ID
NCT01608555
Phase
Phase 4
Status
Completed
Drug / intervention
tobramycin
Sponsor
University of Milan
Start
2012-01
Enrollment
10
Locations
1
About this trial
The study will include 10 adult patients with cystic fibrosis. The aim of the study is to evaluate whether Tobramycin 300 mg aerosol once-a-day for 28 days can reduce the bacterial load in the airways. Secondary end-point is the evaluation of variation in bacterial susceptibility during and at the end of study period.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT01608555 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.